Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025)
Medicus Pharma (MDCX) posted Income from Non-Controlling Interests of -$69.0 for Q4 2025, down 192.0% quarter-over-quarter from $75.0 in Q3 2025.
Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Income from Non-Controlling Interests for 1 consecutive years, with -$69.0 the latest figure, recorded in Q4 2025.
- Income from Non-Controlling Interests for Q4 2025 came in at -$69.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 (changed N/A YoY), and the FY2025 annual result was -$146.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was -$69.0 for Q4 2025 at Medicus Pharma, down from $75.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $75.0 in Q3 2025 and troughed at -$69.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | -69.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -69.00 |
| Sep 30, 2025 | 75.00 |